


Pregnancy in kidney transplantation





Dr F Pourrezagholi SBMU Shahid Labbafinejad Hospital



The history of pregnancy after kidney transplantation starts with young twin sisters:

"In May, 1956, one of a pair of 21-year-old identical twin females from Oklahoma as a recipient from her twin sister".

The donor and recipient have a total of five babies, all of them in good health, at the time NEJM paper was published.



MAGES

With the excellent results of the first pregnancies after KT, the era of pregnancy after kidney transplantation had begun.

After that ,many other successful pregnancies have been reported among the kidney transplant population.

Journal of Nephrology (2018)



PREGNANCY COUNSELLING

Pregnancy counselling should begin when a patient chooses renal replacement therapy.

Although many recipients believe that they can become pregnant with a transplant, there is a possibility of infertility after transplantation.

These facts need to be communicated before the transplant.



PREGNANCY COUNSELLING

Pregnancy can cause kidney function to deteriorate, and poor renal function before pregnancy leads to allograft loss during pregnancy.

Pregnancy should be attempted after renal function has stabilized after transplantation.

Menstrual recovery after transplantation and contraception methods should be explained to recipients to prevent unexpected pregnancy

Preconception counseling

Preconception counseling should be initiated during the pretransplant evaluation.

The following issues should be discussed with the patient prior to, as well as soon after, transplantation:

Pregnancy outcomes (both maternal and fetal) after transplant

•Maternal risks, including both potential obstetric complications and risks to the allograft

Contraceptive methods

Recommended timing of conception after transplant

Management of maintenance immunosuppression before, during, and after pregnancy



CONTRACEPTION


The optimal form of contraception for transplant recipients is not known and is individualized based upon the side-effect profile.

We prefer to delay the start of estrogen-containing contraceptives (pills, ring, or patch) until six weeks posttransplant because of the increased risk of thromboembolic events with estrogen use.




Condoms should always be used to reduce the risk of sexually transmitted infections

More effective









A 25-year-old woman with ESKD from FSGS on maintenance hemodialysis for 6 months received a living donor kidney transplant.

Her creatinine stabilized at 1.0 mg/dl, proteinuria at 0.2 g/g, and BP at 110/70 mm Hg. Her medications included tacrolimus, MMF, prednisone, trimethoprimsulfamethoxazole, and atorvastatin.

At 6 months post-transplant, she indicated the desire to have children.



Can I Become Pregnant?

Timing of conception

The optimal time for conception after kidney transplantation is uncertain.

Based on the 2005 AST, provided that the following conditions are met:

- It has been more than one year since kidney transplantation.
- Graft function is optimal, defined as a serum creatinine of <1.5 mg/dL), with no or minimal proteinuria.
- There have been no episodes of rejection in the previous year.
- •The patient is not on known teratogenic or fetotoxic medications.
- The immunosuppressive regimen is stable at maintenance levels.



- There are no concurrent fetotoxic infections, such as CMV.
- Patients who have a history of recent (but not currently active) CMV disease should be advised to wait at least six months and preferably one year from the resolution of disease before trying to conceive.



Transplantation patients appear to have a lower pregnancy rate than the general public



Pregnancy rate

- The best data come from a longitudinal cohort of 30,078 female transplant recipients aged 15 to 45 years.
- During the first three post transplant years, the pregnancy rate was 33 per 1000 women compared with more than 100 per 1000 women in the general population.



Fertility and Contraceptive Issues After Kidney Transplantation in Women

M. Lessan-Pezeshki, S. Ghazizadeh, M.R. Khatami, M. Mahdavi, E. Razeghi, S. Seifi, F. Ahmadi, and S. Maziar

ABSTRACT

Purpose: Our purpose was to investigate reproductive performance among kidney transplant recipients.

Materials and Methods. We studied 126 kidney transplanted women 15 to 68 years of

PREGNANCY RATES AND FERTILITY IN RENAL TRANSPLANT RECIPIENTS

- There is limited understanding of fertility in women with renal transplants,
- Infertility problems in13out of 126(10.4%) women with renal transplants,5 which is comparable with general population rates.



Many factors drive this low rate:

- the fear of graft loss
- inadequate renal function
- advanced age at the time of transplantation
- better education regarding the use of contraceptive methods



Will My Baby Be OK?



Although the majority of pregnancies after KT result in a **live birth**, the risk of **fetal complications**, such as preterm birth, low birth weight, and IUGR remains high.

Predictors of good maternal and fetal outcomes Include:

a younger maternal age, stable graft function with no recent episodes of graft rejection, serum creatinine level of ,1.5 mg/dl, proteinuria of ,500 mg a day, and normal or well controlled hypertension




Shah et al. BMC Nephrology (2019) 20:24 https://doi.org/10.1186/s12882-019-1213-5

BMC Nephrology

RESEARCH ARTICLE


Open Access





Silvi Shah^{1*}, Renganathan Lalgudi Venkatesan², Ayank Gupta², Maitrik K. Sanghavi², Jeffrey Welge³, Richard Johansen², Emily B. Kean², Taranpreet Kaur¹, Anu Gupta⁴, Tiffany J. Grant² and Prasoon Verma⁵







The results of this meta-analysis show:

Majority of pregnancies in women after kidney transplant result in **live birth**, but maternal and fetal adverse events are common.

Rates of preeclampsia, still birth, and cesarean section were significantly higher than in the

general population.

Live Births among Kidney Transplant Recipients

Paper	Live Births, n	Pregnancies, n		Live Births, %	95% C.I	Weights
Africa			:			
Donnell 1985	22	38	— —	57.895	[41.933; 72.361]	1.8%
Rachdi 2013	16	17		94.118	[67.968; 99.178]	0.4%
Random effects mode		55	-	79.430	[26.433; 97.647]	2.3%
Heterogeneity/ \tilde{r} = 81%, $\tau^{\tilde{r}}$ = 2.	$4282, \chi_1^2 = 5.15 (p = 0.02)$					
Asia						
Aktrurk - 2015	11			68.750		1.1%
Al Duraihimh 2008	174		-	74.359		2.6%
Al Hassani 1995	31			70.455		1.8%
Alfi A Y 2008	20		:	100.000		0.2%
Celik 2011	23		-	74.194		1.5%
Neyatani 2012	17		_ 	50.000	factor and a sound of	1.8%
Park 2001	25	47		53.191		2.0%
Pezeshki 2004	17		-	85.000	[62.416; 95.083]	0.9%
El Houssni 2016	16	21		76.190	[53.966; 89.728]	1.2%
Erman Akar 2015	29			67.442	[52.258; 79.675]	1.9%
Guella 2013	21	33		63.636	[46.266; 78.055]	1.7%
Hau 1994	7	13		53.846	[28.165; 77.636]	1.1%
Hooi 2003	49	72		68.056	[56.486; 77.760]	2.2%
Pour 2005	32	74		43.243		2.3%
Rahamimov 2006	55	69	-	79.710	[68.602; 87.599]	2.0%
Rahbar 1997	11	14		78.571	[50.567; 92.929]	0.9%
Sabagh 1995	44		-	84.615	[72.140; 92.115]	1.6%
Sharma 2009	58			70.732	[60.029; 79.545]	2.2%
Tan 2002	29	42		69.048	[53.697; 81.100]	1.8%
Xu 2011	25	38		65.789	[49.593; 78.987]	1.8%
Yassaee 2007	72	95		75.789	[66.189; 83.350]	2.2%
Yeon 2015	84			70.588	[61.802; 78.071]	2.4%
Yildirim 2005	16	20	÷	80.000	[57.215; 92.287]	1.176
You 2014	30			73.171	[57.748; 84.477]	1,786
Moon 2000	26	48	— •	54.167	[40.114; 67.586]	2.0%
Random effects mode		1322	-	69.057	[64.394; 73.363]	42.1%
$deterpgeneity/^2 = 61\%$, $t^2 = 0$.	1555 v2 = 62.28 (6.40.0)	1)	· ·			

Risk of Fetal Complications

The rate of live births in allograft recipients is comparable to general population and ranges from 71 to 79%. The incidence of preterm delivery has be as high as 40 to 60% versus 5 to 15% in general population.

They have high incidence of preterm birth (52 to 53%), low birth weight (42 to 46%), and IUGR (30 to 50%).



Can I Take My Usual Medications?



Dosing of immunosuppressant medications

There are no guidelines about dosing of immunosuppressant medications during pregnancy, but several studies have provided recommendations

Tacrolimus trough blood levels decreased during the second trimester (from 5.8 2.8 to 4.2 1.8 ng/ml).

cyclosporine levels decreased during the second trimester from 125.1 65.1 to 75.4 35 ng/ml.



MMF is a teratogen and is substituted with azathioprine at least 6 weeks before attempting pregnancy.

Belatacept and mTORinhibitors and should be avoid.

Prednisone is considered safe in pregnancy.

To maintain whole blood drug levels of CNIs a 20%–25% increase in total dose.



May 2017 Volume 91, Issue 5, Pages 1047-1056

Table 3 | Drug safety in pregnancy

Safe	Not safe	Safety not determined
Immunosuppressants		
Tacrolimus	Cyclophosphamide	Sirolimus
Cyclosporin	Mycophenolate products	Everolimus
Azathioprine	Rituximab	
Corticosteroids		
Hydroxychloroquine		
Antihypertensives		
Labetalol	Angiotensin-converting enzyme inhibitors	
Calcium channel antagonists	Angiotensin receptor blockers	
Methyldopa	Minoxidil	
Hydralazine		
Furosemide		
Antibiotics commonly used		
in immunosuppressed patients		
Aciclovir	Ganciclovir	
Valaciclovir	Valganciclovir	
	Co-Trimoxazole	
Lamivudine	Quinolones	
Tenofovir		
Isoniazid		
Nystatin (topical)		



Will I and My Kidney Be OK?



MATERNAL COMPLICATIONS

Preeclampsia: Preeclampsia might be difficult to diagnose in women with renal transplants because many of them have preexisting hypertension, and several develop gestational proteinuria without preeclampsia.

Gestational Diabetes

Women with renal transplants are at higher risk of developing gestational diabetes than the general population. Screening with oral glucose tolerance testing should be offered to all women with renal transplants earlier in gestation.



MATERNAL COMPLICATIONS

Graft Injury During Delivery

This complication is extremely rare and is restricted only to those with surgical deliveries.

Vaginal delivery is not affected by the anatomic location of the graft.

Infections

UTI is the most common infection encountered by women with renal transplants during pregnancy, with incidence rates ranging from 14.6%to 42%. If pregnancy is delayed until at least 1 year after transplantation, the risk for opportunistic infections is likely to be lower.



Pregnancy in Renal Transplant Recipients and Donors

Kate Bramham, PhD

Seminars in Nephrology, Vol 37, No 4, July 2017, pp 370-377

Data from the US National Transplant Pregnancy Registry (NTPR) indicated that women with graft loss during or after pregnancy were more likely to have higher pre pregnancy creatinine than those with stable graft function (1.5 - 0.6 mg/dLversus1.3 0.4 mg/dL) and African-American women have an increased risk for graft loss within 2 years of delivery(13%) in comparison with whites(5%).



The graft failure rate did not differ in pregnant women as compared to non pregnant allograft recipients at follow-up of 10 years (19% versus 21%)

Risk factors associated with graft loss include history of drug treated hypertension, prepregnancy creatinine ≥ 1.4mg/dL, and proteinuria.



Shah et al. BMC Nephrology (2019) 20:24 https://doi.org/10.1186/s12882-019-1213-5

BMC Nephrology

RESEARCH ARTICLE


Open Access





Silvi Shah^{1*}, Renganathan Lalgudi Venkatesan², Ayank Gupta², Maitrik K. Sanghavi², Jeffrey Welge³, Richard Johansen², Emily B. Kean², Taranpreet Kaur¹, Anu Gupta⁴, Tiffany J. Grant² and Prasoon Verma⁵







The results of this meta-analysis show:

Majority of pregnancies in women after kidney transplant result in live birth, but maternal and fetal adverse events are common.

Rates of preeclampsia, still birth, and cesarean section were significantly higher than in the general population.

Live Births among Kidney Transplant Recipients

Paper	Live Births, n	Pregnancies, n		Live Births, %	95% C.I	Weights
Africa						
O' Donnell 1985	22			57.895	[41.933; 72.361]	1.8%
Rachdi 2013	16			94.118	[67.968; 99.178]	0.4%
Random effects model		55		79.430	[26.433; 97.647]	2.3%
Heterogeneity/ = 81%, t = 2.4	$282, \chi_1^2 = 5.15 (\rho = 0.02)$					
Asia						
Aktrurk - 2015	11	16		68.750	[43.323; 86.361]	1,1%
Al Duraihimh 2008	174	234	-	74.359		2.6%
Al Hassani 1995	31	44		70.455	[55.513; 82.005]	1.8%
Alfi A Y 2008	20	20		100.000	[71.262; 99.853]	0.2%
Celik 2011	23	31		74.194	[56.256; 86.536]	1.5%
Neyatani 2012	17	34		50.000	[33.799; 66.201]	1.8%
Park 2001	25	47		53.191	[39.052; 66.836]	2.0%
Pezeshki 2004	17	20		85.000	[62.416; 95.083]	0.9%
El Houssni 2016	16			76.190	[53.966; 89.728]	1.2%
Erman Akar 2015	29			67.442	[52.258; 79.675]	1.9%
Guella 2013	21	33		63.636		1.7%
Hau 1994	7	13		53.846		1.1%
Hooi 2003	49		֥-	68.056	[56.486; 77.760]	2.2%
Pour 2005	32	74		43.243		2.3%
Rahamimov 2006	55	69		79.710	[68.602; 87.599]	2.0%
Rahbar 1997	11	14		78.571	[50.567; 92.929]	0.9%
Sabagh 1995	44	52	 -	84.615		1.6%
Sharma 2009	58	82		70.732		2.2%
Tan 2002	29	42		69.048		1.8%
Xu 2011	25			65.789		1.8%
Yassaee 2007	72			75.789		2.2%
Yeon 2015	84			70.588		2.4%
Yildirim 2005	16		÷-•-	80.000		1.1%
You 2014	30			73.171	[57.748; 84.477]	1.786
Moon 2000	26			54.167	[40.114; 67.586]	2.0%
Random effects model		1322	-	69.057	[64.394; 73.363]	42.1%
Heterogeneity $l^2 = 61\%$, $t^2 = 0.1$	555, $\chi_{24}^2 = 62.28 (p < 0.01)$)				

Most studies have shown that maternal death (defined as death of a pregnant woman or within 42 days of termination of pregnancy) and long-term survival of pregnant transplant recipients appears to be comparable with that of nonpregnant recipients

Long term graft survival and graft function following pregnancy in kidney transplant recipients


a systematic review and meta-analysis

van Buren, Marleen C. MSc^{1,*}; Schellekens, Anouk MD^{2,*}; Groenhof, T. Katrien J. MD³; van Reekum, Franka MD⁴; van de Wetering, Jacqueline MD PhD²; Paauw, Nina D. MD PhD¹; Lely, A. Titia MD PhD¹

Transplantation: October 21, 2019 - Volume Online First - Issue - p

doi: 10.1097/TP.0000000000003026

This study is an updated meta-analysis on graft survival with comparison with nonpregnant KT recipients and for the first time long-term follow up (up to 10 year) of graft function after pregnancy.



GL and **SCr** after pregnancy in KT recipients when compared to nulliparous KT recipients are **stable** up to 10 years postpartum.

Systematic review of the literature showed that mainly **pre pregnancy proteinuria**, **hypertension** and **high SCr** are risk factors for GL.

	post-pregnancy SCr mg/dl			pre-pregnancy SCr mg/dl		Mean Difference		Mean Difference	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
Abe 2008	1.29	0.51	20	1.15	0.27	20	8.6%	0.14 [-0.11, 0.39]	
Alfi 2008	1.76	2.15	12	1.24	0.27	12	1.1%	0.52 [-0.71, 1.75]	
Areia 2009	1.34	0.95	28	1.29	0.34	28	6.3%	0.05 [-0.32, 0.42]	
Candido 2016	1.59	0.2	36	1.19	0.07	36	12.1%	0.40 [0.33, 0.47]	*
Crowe 1999	1.91	1.18	29	1.77	1.18	29	3.5%	0.14 [-0.47, 0.75]	
Galdo 2005	1.38	0.53	30	1.19	0.38	30	9.0%	0.19 [-0.04, 0.42]	-
Gorgulu 2010	1.15	0.29	19	1.06	0.3	19	10.0%	0.09 [-0.10, 0.28]	
Hooi 2003	1.35	0.44	46	1.27	0.37	46	10.5%	0.08 [-0.09, 0.25]	+-
Kato 2012	1.4	0.8	21	1.16	0.39	21	6.2%	0.24 [-0.14, 0.62]	-
Keitel 2004	2	1.8	40	1.2	0.5	41	3.7%	0.80 [0.22, 1.38]	
Kim 2008	1.1	0.98	48	1.12	0.25	49	7.9%	-0.02 [-0.31, 0.27]	
Kwek 2015	2.23	1.26	10	1.39	0.25	10	2.3%	0.84 [0.04, 1.64]	
Stoumpos 2016	1.62	1.21	76	1.45	0.87	83	7.1%	0.17 [-0.16, 0.50]	
Yildirim 2005	1.19	0.12	17	1.18	0.16	17	11.8%	0.01 [-0.09, 0.11]	+
Total (95% CI)			432			441	100.0%	0.18 [0.05, 0.32]	•
Heterogeneity: Tau ² =	0.04; Chi2 =	59.80, df -	13 (P <	0.00001); 12	= 78%				12 1
Test for overall effect			1177 7.00		H //278				-2 -1 0 1 < SCr post-pregnancy > SCr post-pregnancy



Will I Need a Cesarean Section, and Can I Breastfeed?



- □ Vaginal delivery is well tolerated and recommended in uncomplicated pregnancies.
- Cesarean section should be done for obstetric indications
- In the event of surgery, care should be taken to avoid injury to the ureter of the kidney allograft/.

J Nephrol 31: 665-681, 2018,



Breast-Feeding

Transplant recipients taking prednisone, azathioprine, cyclosporine, and tacrolimus should not be discouraged from breast-feeding.



It is well established now that the infants who are breast-fed by mothers on prednisone, azathioprine, and cyclosporine/tacrolimus have a lesser exposure via breast milk than in utero and they do not have adverse effects.



Breast feeding is recommended by the American Association of Pediatrics for the first 6 months of life and this practice is not opposed by the American Society of Transplantation.

Although low levels of drug and drug metabolites can be detected in breast milk, a regimen of tacrolimus, azathioprine and prednisone is felt to be safe.



Follow-Up of This Patient

This patient did not wish to delay pregnancy.

MMF was switched to azathioprine.

Aspirin 81 mg daily was started.

Trimethoprim- sulfamethoxazole and atorvastatin were stopped.

She became pregnant at about 10 months post-transplant.



Her BP remained well controlled without medications.

Although there was a small increase in proteinuria to 0.5 g/g, her serum creatinine improved from 1.0 to 0.8 mg/dl.



- She was induced at 36 weeks of gestation because of an abrupt rise in serum creatinine, and had a cesarean section delivery for a nonreassuring fetal heart rate.
- Her baby was healthy but of low birth weight.
- She elected not to breast feed.
- Her creatinine returned to baseline post delivery and has
- remained stable 2 years post-transplant.







THANK YOU

